316 related articles for article (PubMed ID: 37831146)
1. PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies.
Lin KX; Istl AC; Quan D; Skaro A; Tang E; Zheng X
Cancer Immunol Immunother; 2023 Dec; 72(12):3875-3893. PubMed ID: 37831146
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: From bench to bedside.
Lizardo DY; Kuang C; Hao S; Yu J; Huang Y; Zhang L
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188447. PubMed ID: 33035640
[TBL] [Abstract][Full Text] [Related]
3. Current progress and future perspectives of neoadjuvant anti-PD-1/PD-L1 therapy for colorectal cancer.
Yang Z; Wu G; Zhang X; Gao J; Meng C; Liu Y; Wei Q; Sun L; Wei P; Bai Z; Yao H; Zhang Z
Front Immunol; 2022; 13():1001444. PubMed ID: 36159842
[TBL] [Abstract][Full Text] [Related]
4. Application of immune checkpoint inhibitors in colorectal cancer.
Wang L; Huang C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Aug; 46(8):894-899. PubMed ID: 34565736
[TBL] [Abstract][Full Text] [Related]
5. Clinical trials of neoadjuvant immune checkpoint inhibitors for early-stage operable colon and rectal cancer.
Veen T; Kanani A; Lea D; Søreide K
Cancer Immunol Immunother; 2023 Oct; 72(10):3135-3147. PubMed ID: 37528319
[TBL] [Abstract][Full Text] [Related]
6. Latest evidence on immune checkpoint inhibitors in metastatic colorectal cancer: A 2022 update.
Boukouris AE; Theochari M; Stefanou D; Papalambros A; Felekouras E; Gogas H; Ziogas DC
Crit Rev Oncol Hematol; 2022 May; 173():103663. PubMed ID: 35351582
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib in combination with immune checkpoint inhibitors for mismatch repair proficient (pMMR)/microsatellite stable (MSS) colorectal cancer.
Akin Telli T; Bregni G; Vanhooren M; Saude Conde R; Hendlisz A; Sclafani F
Cancer Treat Rev; 2022 Nov; 110():102460. PubMed ID: 36058142
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond.
Cohen R; Rousseau B; Vidal J; Colle R; Diaz LA; André T
Target Oncol; 2020 Feb; 15(1):11-24. PubMed ID: 31786718
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of anti-PD-1/PD-L1 therapy in the treatment of advanced colorectal cancer: a meta-analysis.
Li Y; Du Y; Xue C; Wu P; Du N; Zhu G; Xu H; Zhu Z
BMC Gastroenterol; 2022 Oct; 22(1):431. PubMed ID: 36217119
[TBL] [Abstract][Full Text] [Related]
10. Beyond Microsatellite Instability: Evolving Strategies Integrating Immunotherapy for Microsatellite Stable Colorectal Cancer.
Pecci F; Cantini L; Bittoni A; Lenci E; Lupi A; Crocetti S; Giglio E; Giampieri R; Berardi R
Curr Treat Options Oncol; 2021 Jun; 22(8):69. PubMed ID: 34110510
[TBL] [Abstract][Full Text] [Related]
11. A new strategy for immunotherapy of microsatellite-stable (MSS)-type advanced colorectal cancer: Multi-pathway combination therapy with PD-1/PD-L1 inhibitors.
Cai L; Chen A; Tang D
Immunology; 2024 Mar; ():. PubMed ID: 38517066
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors in pMMR/MSS Colorectal Cancer.
El Hajj J; Reddy S; Verma N; Huang EH; Kazmi SM
J Gastrointest Cancer; 2023 Dec; 54(4):1017-1030. PubMed ID: 37009977
[TBL] [Abstract][Full Text] [Related]
13. The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma.
Almquist DR; Ahn DH; Bekaii-Saab TS
BioDrugs; 2020 Jun; 34(3):349-362. PubMed ID: 32246441
[TBL] [Abstract][Full Text] [Related]
14. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
[TBL] [Abstract][Full Text] [Related]
15. How to overcome resistance to immune checkpoint inhibitors in colorectal cancer: From mechanisms to translation.
Wang Q; Shen X; Chen G; Du J
Int J Cancer; 2023 Aug; 153(4):709-722. PubMed ID: 36752642
[TBL] [Abstract][Full Text] [Related]
16. Case Report: Genetic and immune microenvironmental characteristics of a rectal cancer patient with MSS/PD-L1-negative recurrent hepatopulmonary metastasis who achieved complete remission after treatment with PD-1 inhibitor.
Song Y; Long J; Su X; Chen Z; He Y; Shao W; Wang B; Chen C
Front Immunol; 2023; 14():1197543. PubMed ID: 37520536
[TBL] [Abstract][Full Text] [Related]
17. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
[TBL] [Abstract][Full Text] [Related]
18. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part II-The Challenge of Programmed Death Ligand-1 Testing and Its Role in Microsatellite Instability-High Colorectal Cancer.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):26-34. PubMed ID: 29120224
[TBL] [Abstract][Full Text] [Related]
19. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
[TBL] [Abstract][Full Text] [Related]
20. Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy.
Yi B; Cheng H; Wyczechowska D; Yu Q; Li L; Ochoa AC; Riker AI; Xi Y
Mol Cancer Ther; 2021 Jul; 20(7):1295-1304. PubMed ID: 33879557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
